542,351

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/064837 A1

(51) International Patent Classification[7]: A61K 31/44, C07D 213/84, A61P 31/04

(21) International Application Number: PCT/US2004/001327

(22) International Filing Date: 16 January 2004 (16.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/441,411 17 January 2003 (17.01.2003) US

(71) Applicants *(for all designated States except US)*: **GENOME THERAPEUTICS CORPORATION** [US/US]; 100 Beaver Street, Waltham, MA 02453-8443 (US). **ARQULE** [US/US]; 19 Presidential Way, Woburn, MA 01801-5140 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MOIR, Donald, T.** [US/US]; 112 Bertwell Road, Lexington, MA 02420 (US). **XIANG, Yibin** [CA/US]; 831 Main Street, Acton, MA 01720 (US). **ARVANITES, Anthony, C.** [US/US]; 329 Cedar Street, New Bedford, MA 02740-4503 (US). **ALI, Syed, Masarrat** [IN/US]; 409 Waverly Road, North Andover, MA 01845 (US). **GENG, Bolin** [US/US]; 31 Suncrest Road, Andover, MA 01810 (US). **ASHWELL, Mark, A.** [GB/US]; 8 Heald Road, Carlisle, MA 01741 (US). **ORGUEIRA, Hernan, Antonio** [AR/US]; 60 Ellery Street, Apartment #9, Cambridge, MA 02138 (US).

(74) Agents: **DAVIS, Steven, G.** et al.; Hamilton, Brook, Smith & Reynolds, P.C., 530 Virginia Road, P.O. Box 9133, Concord, Massachusetts 01742-9133 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTIBACTERIAL FAB I INHIBITORS



(Ia)



(Ib)

(57) Abstract: Disclosed herein are antibacterial compounds that inhibit *fabI*, a NADH-dependent enoyl [acyl carrier protein] reductase enzyme in the fatty acid biosynthesis pathway. The compounds are represented by structural formulas Ia and Ib: R1 and R2 are independently monocyclic aryl or heteroaryl groups, wherein the groups represented by R1 and R2 are optionally substituted with one or more acyclic substituents; R3 is -H or an optionally substituted C1-C8 aliphatic, C3-C8 cycloaliphatic, aryl, or heteroaryl group. X1 is a bond or a C1-C3 alkylene chain that is optionally substituted with a C1-C4 alkyl or an acidic group. X2 is an aryl, heteroaryl or C3-C8 cycloaliphatic ring, wherein the group represented by X2 is optionally substituted with triazole, tetrazole, and/or one or more acyclic substituents.

WO 2004/064837 A1